|
Molassiotis [47]
|
2010
|
survey study
|
no data
|
no data
|
second or third line for refractory chemotherapy-related nausea and vomiting
|
|
Stephenson [48]
|
2006
|
non-comparative prospective study
|
no data
|
6.25–25
|
first line in indeterminate pathophysiological causes and second line for all other causes of nausea and vomiting
|
|
Eisenchlas [13]
|
2005
|
open-label prospective study
|
6.25
|
3.12- 25
|
second line
|
|
Amesbury [49]
|
2004
|
case report
|
no data
|
12.5 -25
|
first line indication: 5HT2 antagonist property of levomepromazine is used because large amounts of circulating 5-HT are present in carcinoid syndrome
|
|
Kennett [50]
|
2004
|
quasi experimental prospective study
|
no data
|
6.25-25
|
second line or for indeterminate pathophysiological causes
|
|
Higi [51]
|
1980
|
prospective study
|
no data
|
16-30
|
second line in chemotherapy induced nausea
|
|
Davis [23]
|
2010
|
SR
|
nox data
|
no data
|
based on [13, 49, 50]
|
|
Glare [52]
|
2004
|
SR
|
no data
|
no data
|
based on one study [55] (not available)
|
